How to buy Intersect ENT stock

Intersect ENT Inc is a health care equipment & supplies business based in the US. Intersect ENT shares (XENT) are listed on the NASDAQ and all prices are listed in US Dollars. Intersect ENT employs 433 staff and has a trailing 12-month revenue of around $106.7 million.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Intersect ENT stock price (NASDAQ: XENT)

Use our graph to track the performance of XENT stocks over time.

Intersect ENT shares at a glance

• Key figures

Information last updated 2022-10-02.

Latest market close	$28.24
52-week range	$26.66 - $28.25
50-day moving average more info button	$27.83
200-day moving average more info button	$27.38
Wall St. target price	$28.25
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-4.80

Buy Intersect ENT shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intersect ENT stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intersect ENT price performance over time

Historical closes compared with the close of $28.24 from 2022-05-13

1 week (2022-09-22)	N/A
1 month (2022-08-30)	N/A
3 months (2022-06-29)	N/A
6 months (2022-03-30)	0.79%

1 year (2021-10-01)	3.71%
2 years (2020-10-02)	74.43%
3 years (2019-10-03)	65.78%
5 years (2017-10-03)	29.5

Intersect ENT financials

Revenue TTM	$106.7 million
Gross profit TTM	$76.7 million
Return on assets TTM	-23.28%
Return on equity TTM	-181.73%
Profit margin	-149.54%
Book value	$0.49
Market capitalisation more info button	$954.9 million

TTM: trailing 12 months

Intersect ENT share dividends

We're not expecting Intersect ENT to pay a dividend over the next 12 months.

Have Intersect ENT's shares ever split?

Intersect ENT's shares were split on a 1:4 basis on 11 July 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intersect ENT shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intersect ENT shares which in turn could have impacted Intersect ENT's share price.

Intersect ENT share price volatility

Over the last 12 months, Intersect ENT's shares have ranged in value from as little as $26.66 up to $28.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intersect ENT's is 1.5289. This would suggest that Intersect ENT's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intersect ENT overview

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009.

Frequently asked questions

What percentage of Intersect ENT is owned by insiders or institutions?
Currently 1.503% of Intersect ENT shares are held by insiders and 93.596% by institutions. How many people work for Intersect ENT?
Latest data suggests 433 work at Intersect ENT. When does the fiscal year end for Intersect ENT?
Intersect ENT's fiscal year ends in December. Where is Intersect ENT based?
Intersect ENT's address is: 1555 Adams Drive, Menlo Park, CA, United States, 94025 What is Intersect ENT's ISIN number?
Intersect ENT's international securities identification number is: US46071F1030 What is Intersect ENT's CUSIP number?
Intersect ENT's Committee on Uniform Securities Identification Procedures number is: 46071F103